Technical Analysis for OPK - OPKO Health Inc.

Grade Last Price % Change Price Change
grade C 1.595 -0.31% -0.01
OPK closed up 0.95 percent on Wednesday, February 19, 2020, on 47 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Flat
Historical OPK trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction -0.31%
NR7 Range Contraction -0.31%
Crossed Above 20 DMA Bullish 0.63%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.63%
20 DMA Resistance Bearish 1.59%
50 DMA Support Bullish 1.59%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.59%
Fell Below 20 DMA Bearish 1.59%
NR7 Range Contraction -1.54%
Inside Day Range Contraction -1.54%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. The company is developing molecular diagnostics tests to identify molecules or immunobiomarkers for Alzheimer's disease, non-small cell lung cancer, and pancreatic cancer, and other cancers; point-of-care diagnostic tests to detect prostate specific antigen; and laboratory developed tests comprising 4Kscore test for the detection of prostate cancer. It also operates OURLab, a full-service medical laboratory specializing in urologic pathology. In addition, the company is developing CTAP101 Capsules to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; and Fermagate Tablets to treat hyperphosphatemia in end-stage renal disease patients on chronic hemodialysis. Further, it is developing oligonucleotide therapeutics, which are under pre-clinical studies for the treatment of various illnesses, such as cancer, heart disease, metabolic disorders, and genetic anomalies; heparin-derived oligosaccharide for asthma and chronic obstructive pulmonary diseases; influenza vaccines; alpha-galactosyl ceramide analogs for cancer, infectious disease, and autoimmune disease; and rolapitant, a NK-1 candidate that has completed Phase II clinical testing for the prevention of chemotherapy induced nausea and vomiting. Additionally, the company develops and produces specialty active pharmaceutical ingredients; offers ophthalmic and other pharmaceutical products; and provides cardiovascular products, vaccines, antibiotics, gastro-intestinal products, and hormones. It operates in the United States, Chile, Mexico, Israel, and Spain. OPKO Health, Inc. is based in Miami, Florida.
Health Cancer Cancers Chemotherapy Pharmaceutical Industry In China Prostate Cancer Clinical Trial Alzheimer's Disease Non Small Cell Lung Cancer Influenza Diagnostic Tests Medical Tests Antibiotics Active Pharmaceutical Ingredients Asthma Chronic Kidney Disease Molecular Diagnostics Pancreatic Cancer Hemodialysis End Stage Renal Disease Infectious Disease Autoimmune Disease Nausea Metabolic Disorders Cardiovascular Products Heart Disease Vomiting Chronic Obstructive Pulmonary Diseases Organ Failure Secondary Hyperparathyroidism Hyperphosphatemia Such As Cancer

Is OPK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 2.88
52 Week Low 1.33
Average Volume 3,725,823
200-Day Moving Average 1.84
50-Day Moving Average 1.54
20-Day Moving Average 1.58
10-Day Moving Average 1.59
Average True Range 0.07
ADX 11.64
+DI 20.46
-DI 19.75
Chandelier Exit (Long, 3 ATRs ) 1.56
Chandelier Exit (Short, 3 ATRs ) 1.63
Upper Bollinger Band 1.70
Lower Bollinger Band 1.45
Percent B (%b) 0.6
BandWidth 15.60
MACD Line 0.01
MACD Signal Line 0.01
MACD Histogram 0.0025
Fundamentals Value
Market Cap 895.15 Million
Num Shares 559 Million
EPS -0.15
Price-to-Earnings (P/E) Ratio -10.67
Price-to-Sales 3.13
Price-to-Book 1.76
PEG Ratio -2.91
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.65
Resistance 3 (R3) 1.64 1.63 1.64
Resistance 2 (R2) 1.63 1.62 1.63 1.63
Resistance 1 (R1) 1.61 1.61 1.62 1.62 1.63
Pivot Point 1.60 1.60 1.60 1.60 1.60
Support 1 (S1) 1.58 1.59 1.59 1.59 1.57
Support 2 (S2) 1.57 1.58 1.57 1.57
Support 3 (S3) 1.55 1.57 1.56
Support 4 (S4) 1.56